Literature DB >> 17448997

Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex.

Min Wang1, Brian P Ramos, Constantinos D Paspalas, Yousheng Shu, Arthur Simen, Alvaro Duque, Susheel Vijayraghavan, Avis Brennan, Anne Dudley, Eric Nou, James A Mazer, David A McCormick, Amy F T Arnsten.   

Abstract

Spatial working memory (WM; i.e., "scratchpad" memory) is constantly updated to guide behavior based on representational knowledge of spatial position. It is maintained by spatially tuned, recurrent excitation within networks of prefrontal cortical (PFC) neurons, evident during delay periods in WM tasks. Stimulation of postsynaptic alpha2A adrenoceptors (alpha2A-ARs) is critical for WM. We report that alpha2A-AR stimulation strengthens WM through inhibition of cAMP, closing Hyperpolarization-activated Cyclic Nucleotide-gated (HCN) channels and strengthening the functional connectivity of PFC networks. Ultrastructurally, HCN channels and alpha2A-ARs were colocalized in dendritic spines in PFC. In electrophysiological studies, either alpha2A-AR stimulation, cAMP inhibition or HCN channel blockade enhanced spatially tuned delay-related firing of PFC neurons. Conversely, delay-related network firing collapsed under conditions of excessive cAMP. In behavioral studies, either blockade or knockdown of HCN1 channels in PFC improved WM performance. These data reveal a powerful mechanism for rapidly altering the strength of WM networks in PFC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17448997     DOI: 10.1016/j.cell.2007.03.015

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  279 in total

1.  Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory.

Authors:  E Y Yuen; W Liu; I N Karatsoreos; Y Ren; J Feng; B S McEwen; Z Yan
Journal:  Mol Psychiatry       Date:  2010-05-11       Impact factor: 15.992

Review 2.  The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Amy F T Arnsten
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

3.  Cognitive activation by central thalamic stimulation: the yerkes-dodson law revisited.

Authors:  Robert G Mair; Kristen D Onos; Jacqueline R Hembrook
Journal:  Dose Response       Date:  2010-08-20       Impact factor: 2.658

4.  Corticotropin-releasing factor in the norepinephrine nucleus, locus coeruleus, facilitates behavioral flexibility.

Authors:  Kevin Snyder; Wei-Wen Wang; Rebecca Han; Kile McFadden; Rita J Valentino
Journal:  Neuropsychopharmacology       Date:  2011-10-12       Impact factor: 7.853

Review 5.  A neurochemical yin and yang: does serotonin activate and norepinephrine deactivate the prefrontal cortex?

Authors:  Paul J Fitzgerald
Journal:  Psychopharmacology (Berl)       Date:  2010-04-13       Impact factor: 4.530

6.  Erratum: alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder.

Authors:  L Cinnamon Bidwell; Rachel E Dew; Scott H Kollins
Journal:  Curr Psychiatry Rep       Date:  2011-02       Impact factor: 5.285

7.  Persistent activity in a cortical-to-subcortical circuit: bridging the temporal gap in trace eyelid conditioning.

Authors:  Jennifer J Siegel; Brian Kalmbach; Raymond A Chitwood; Michael D Mauk
Journal:  J Neurophysiol       Date:  2011-09-28       Impact factor: 2.714

Review 8.  Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents.

Authors:  Hannah Weisman; Imraan A Qureshi; James F Leckman; Lawrence Scahill; Michael H Bloch
Journal:  Neurosci Biobehav Rev       Date:  2012-10-23       Impact factor: 8.989

Review 9.  HCN Channel Targets for Novel Antidepressant Treatment.

Authors:  Stacy M Ku; Ming-Hu Han
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

10.  A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures.

Authors:  Laura C Politte; Lawrence Scahill; Janet Figueroa; James T McCracken; Bryan King; Christopher J McDougle
Journal:  Neuropsychopharmacology       Date:  2018-02-27       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.